Dementia is a progressive condition that gradually impairs cognitive function, memory, and daily living skills. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Preliminary findings suggest these adaptations improved nursing assistant engagement, consistency in strategy use, and resident interaction quality. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
La enfermedad de Alzheimer (EA) es la demencia neurodgenerativa más prevalente a nivel mundial, en los últimos años se ha resaltado su relación con los trastornos del sueño y la desregulación de la melatonina. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Introdução: Avanços recentes na pesquisa de biomarcadores e estruturas diagnósticas, como o sistema de classificação ATN, redefiniram a abordagem do diagnóstico e tratamento precoces. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ResumenLa enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa crónica que se caracteriza por la acumulación excesiva de proteína beta-amiloide y de proteína Tau fosforilada. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26/100
El Alzheimer es un trastorno neurodegenerativo que afecta la cognición y memoria. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Penyakit Alzheimer adalah jenis demensia akibat kerusakan pada neuron otak yang memengaruhi memori, bahasa, dan berpikir. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Studies in Jalisco have identified a mutation in the PSEN1 gene, associated with early-onset Alzheimer's. This variant, common in the Altos de Jalisco region, affects both men and women, causing severe symptoms such as difficulty walking and speaking. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sequencing revealed a biallelic SORL1 splice donor variant (c.1211 + 1G > A). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Introdução: A doença de Alzheimer (DA) é uma condição neurodegenerativa progressiva, caracterizada pelo acúmulo de placas de β-amiloide e emaranhados neurofibrilares. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Con el envejecimiento de la población general, el número de pacientes con epilepsia de inicio tardío crece constantemente. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Este artículo cuestiona la dicotomía entre realismo y constructivismo en la filosofía de la ciencia, argumentando que resulta insuficiente para comprender entidades biomédicas como el Alzheimer. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26/100
A Doença de Alzheimer (DA) é uma enfermidade neurodegenerativa progressiva cuja detecção precoce é essencial para intervenções terapêuticas eficazes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26/100
Otępienie to zespół objawów wywołany postępującymi chorobami neurodegeneracyjnymi mózgu, które prowadzą do znacznego pogorszenia funkcji poznawczych, a w końcowym etapie do całkowitej zależności pacjenta od otoczenia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this study, a preliminary reliability assessment on the Chinese version of the EOLD scale was conducted, revealing that the three subscales exhibit strong internal consistency in reliability and structural validity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared to direct estimation, the HB SAE model reduced the number of sub-districts with Relative Standard Errors (RSE) above 25% from 55 to 44, achieving lower Mean Squared Error (MSE) values and more stable estimates. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Ukiyo Project is a collaborative initiative between the Faculty of Fine Arts at the Complutense University of Madrid (UCM) and the Faculty of Psychology at the University of Guanajuato (Mexico), aimed at promoting emotional well-being and mental health in the university environment through art. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS), caused by trisomy of chromosome 21, exhibits significant phenotypic variability, including intellectual disability, early-onset Alzheimer disease (AD), congenital heart defects (CHDs), haematological malignancies, and immune dysregulation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease is one of the causes of dementia that could make the patient lose their memories until they unable to do normal activities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
La enfermedad de Alzheimer (EA) fue descrita por primera vez en una mujer, Augusta D, cuyo caso reveló las características neuropatológicas clásicas de placas amiloides y ovillos neurofibrilares. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A doença de Alzheimer (DA) configura-se como a principal causa de demência em idosos, se tornando um dos maiores desafios da medicina moderna devido à sua alta prevalência e o impacto social associado. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
25/100
This study examined how the COVID-19 pandemic altered the sociologic, individual, and biologic personhood of residents living with dementia in nursing homes, guided by Buron’s (2008) Personhood Model for Dementia Care (PMDC). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease manifests through heterogeneous progression patterns across diverse populations, yet current predictive models fail to capture this complexity while maintaining clinical interpretability. 4 key findings →
Design: longitudinal study Participants: 1,669 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
16/100
Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. 4 key findings →
Design: longitudinal study Participants: 237 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events